موقع الهيئة الجديد

حمل التطبيق 
Date issuedProductSafety information
15/04/41 Kyprolis® ( Carfilzomib)

Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation.CLICK HERE
11/04/41 Esbriet® (Pirfenidone)

Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI).CLICK HERE
17/03/41 FEGONA®

FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception ​. CLICK HERE​​​​​
22/02/41 Zofran®

Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron)  . CLICK HERE​​​​​​
20/01/41 Methotrexate "Ebewe”

​Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases ​CLICK HERE​​​​​
12/01/41 Roaccutne

Roaccutne (isotretinoin): An update on neuropsychiatric disorders.CLICK HERE​​​​
25/12/40 soliqua (lixisenatide /insuline glargin) soliqua

(lixisenatide /insuline glargin):  Important information on dosing.CLICK HERE​​​
25/12/40 Advaquin ( levofloxacin)

Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE​​​
07/12/40 Gilenya (fingolimod)

Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.CLICK HERE​​​​
28/10/40 Darzalex (Daratumumab)

Darzalex (Daratumumab): New identified risk of hepatitis B reactivation.CLICK HERE​​​
12345...الأخيرة